Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 5
1968 1
1970 1
1971 1
1972 1
1973 2
1974 2
1975 1
1977 1
1980 4
1982 3
1983 1
1986 2
1988 2
1989 8
1990 1
1991 5
1992 4
1993 9
1994 8
1995 3
1996 7
1997 7
1998 9
1999 3
2000 13
2001 9
2002 11
2003 10
2004 6
2005 8
2006 13
2007 13
2008 12
2009 8
2010 8
2011 9
2012 9
2013 11
2014 5
2015 2
2016 2
2017 3
2018 3
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

240 results
Results by year
Filters applied: . Clear all
Page 1
Diphtheria toxin-based targeted toxin therapy for brain tumors.
Li YM, et al. J Neurooncol 2013 - Review. PMID 23695514
After internalization, the toxin component kills the cell. These recombinant proteins consist of an antibody or carrier ligand coupled to a modified plant or bacterial toxin such as diphtheria toxin (DT). ...TT have shown an acceptable profile for toxicity and safety in animal studies and early clinical trials have demonstrated a therapeutic response. ...
After internalization, the toxin component kills the cell. These recombinant proteins consist of an antibody or carrier ligand couple …
Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
Cheung LS, et al. Proc Natl Acad Sci U S A 2019. PMID 30718426 Free PMC article.
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25-positive cells including regulatory T cells and has been approved for the treatment of persistent or recurrent cutaneous T cell lymphoma. However, the clinical use of denileukin diftitox was limited by vascular leak toxicity and production issues related to drug aggregation and purity. ...
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25-positive cells including r …
Denileukin diftitox
Figgitt DP, et al. Am J Clin Dermatol 2000 - Review. PMID 11702307
Denileukin diftitox is a novel interleukin-2 receptor (IL-2R)-targeted diphtheria toxin. It binds to cells expressing IL-2R and inhibits protein synthesis through internalization of the diphtheria toxin fragment. ...
Denileukin diftitox is a novel interleukin-2 receptor (IL-2R)-targeted diphtheria toxin. It binds to cells expressing IL-2R an …
Diphtheria toxin fusion proteins.
Foss FM, et al. Curr Top Microbiol Immunol 1998 - Review. PMID 9670613
A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin.
Peraino JS, et al. J Immunol Methods 2013. PMID 23470981 Free PMC article.
Targeted cell therapies are possible through the generation of recombinant fusion proteins that combine a toxin, such as diphtheria toxin (DT), with an antibody or other molecule that confers specificity. Upon binding of the fusion protein to the cell of interest, the diphtheria toxin is internalized which results in protein synthesis inhibition and subsequent cell death. ...
Targeted cell therapies are possible through the generation of recombinant fusion proteins that combine a toxin, such as diphtheri
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V, et al. Blood 2014 - Clinical Trial. PMID 24719405 Free PMC article.
In 42 patients, donor NK cell expansion was detected in 10%, whereas in 15 patients receiving host Treg depletion with the IL-2-diphtheria fusion protein (IL2DT), the rate was 27%, with a median absolute count of 1000 NK cells/μL blood. ...
In 42 patients, donor NK cell expansion was detected in 10%, whereas in 15 patients receiving host Treg depletion with the IL-2-diphtheri
Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19(+) tumors.
Zheng Q, et al. Mol Oncol 2017. PMID 28306193 Free PMC article.
We have developed a diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19(+) tumors. We have constructed three isoforms of the CD19 immunotoxin: monovalent, bivalent, and foldback diabody. ...The bivalent CD19 immunotoxin is a promising therapeutic drug candidate for targeting relapsing/refractory human CD19(+) tumors....
We have developed a diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19(+) tumors. We have constructed …
Targeting diphtheria toxin to growth factor receptors.
Murphy JR and vanderSpek JC. Semin Cancer Biol 1995 - Review. PMID 8562903
Biochemical, genetic and X-ray crystallographic analysis of diphtheria toxin have demonstrated that the native toxin is composed of three structural domains that function in an ordered fashion to intoxicate a eukoryotic cell. ...To date, administration of the diphtheria toxin-based fusion proteins targeted toward the high affinity IL-2 receptor have been found to be safe, well tolerated, and capable of inducing remission in refractory hematologic malignancies....
Biochemical, genetic and X-ray crystallographic analysis of diphtheria toxin have demonstrated that the native toxin is …
Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs.
Sánchez-García L, et al. J Control Release 2018. PMID 29408658
In this context, we have here engineered potent protein toxins, namely segments of the diphtheria toxin and the Pseudomonas aeruginosa exotoxin as self-assembling, self-delivered therapeutic materials targeted to CXCR4(+) cancer stem cells. ...
In this context, we have here engineered potent protein toxins, namely segments of the diphtheria toxin and the Pseudomonas ae …
Optimal route of diphtheria toxin administration to eliminate native nephron progenitor cells in vivo for kidney regeneration.
Fukunaga S, et al. Biochem Biophys Res Commun 2018. PMID 29408475
To address the lack of organs for transplantation, we previously developed a method for organ regeneration in which nephron progenitor cell (NPC) replacement is performed via the diphtheria toxin receptor (DTR) system. ...
To address the lack of organs for transplantation, we previously developed a method for organ regeneration in which nephron progenitor cell …
240 results
Jump to page
Feedback